Cytotoxic activity of allogeneic anti-CD38 CAR-γδ T cells in myeloma shows significant tumor inhibition, indicating potential for wider clinical application.
Key Points
Cytotoxic activity of fully human anti-CD38-CAR γδ T cells effectively eliminated myeloma cells in vitro and in vivo.
In vitro studies revealed over 90% cytotoxic activity when exposed to myeloma cells at a 1:2 ratio for 48 hours.
Observational analysis of xenograft models demonstrated myeloma growth inhibition by CAR-γδ T cells monitored using in vivo imaging.
These findings support the feasibility of allogeneic CAR-γδ T cells as an off-the-shelf therapy for myeloma patients.